News | August 16, 2021
IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Income declines marginally
The company has strong product launches both in India and overseas
Board declares interim dividend of Rs 2 per equity share
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
Forex gains stood at Rs 20 crore for the quarter
Subscribe To Our Newsletter & Stay Updated
